

Merck Kommanditgesellschaft auf Aktien

Darmstadt

Germany

- ISIN DE 000 659 990 5 -

- Securities Identification No. 659 990 -

The shareholders of our company are hereby invited to attend the

Annual General Meeting

on Friday, April 26, 2019 at 10:00 a.m. CEST

held at the

**Jahrhunderthalle Frankfurt, Pfaffenwiese 301, 65929 Frankfurt am
Main, Germany.**



Agenda

1. Presentation of the annual financial statements approved by the Supervisory Board, as well as the consolidated financial statements approved by the Supervisory Board and the combined management report (including the explanatory report on the information in accordance with Section 289a (1), Section 315a (1) HGB) for fiscal 2018 and the Report of the Supervisory Board

The Supervisory Board has approved the annual financial statements and the consolidated financial statements which were prepared by the Executive Board in accordance with Section 171 of the German Stock Corporation Act, (hereinafter "AktG"). In accordance with Section 286 (1) AktG, Article 29 (3) of the Articles of Association, the annual financial statements are to be adopted by the General Meeting (Item 2 of the Agenda). The aforementioned documents will be available on the company's website as of the date on which the Annual General Meeting is convened. In addition, they will be available for inspection by the limited shareholders (also referred to hereinafter as "shareholders") at the business offices of the company once the Annual General Meeting has been convened (for more information see the section titled "Information and Documents for the Annual General Meeting; company website"). No resolution is required for Item 1 of the Agenda.

2. Resolution on the adoption of the annual financial statements for fiscal 2018

The Executive Board and the Supervisory Board propose that the presented annual financial statements of the company for the year ended December 31, 2018 be approved.

3. Resolution authorizing the appropriation of the net retained profit for fiscal 2018

The Executive Board and the Supervisory Board propose that the share of the net retained profit of the company attributable to the shareholders amounting to € 187,277,260.03 be appropriated as follows:

- a) Payment of a dividend of € 1.25 per no par value share of the dividend-bearing share capital as of the date of this Annual General Meeting, being € 161,552,815.00 in total.
- b) Carryforward of the remaining amount of € 25,724,445.03 to new account.

Dividends are payable on the third business day after the General Meeting passing the resolution on the dividend, i.e. on May 2, 2019.

4. Resolution on the approval of the actions of the Executive Board for fiscal 2018

The Executive Board and the Supervisory Board propose that the actions of the members of the Executive Board in office in fiscal 2018 be approved for their activities in fiscal 2018.

5. Resolution on the approval of the actions of the Supervisory Board for fiscal 2018

The Executive Board and the Supervisory Board propose that the actions of the members of the Executive Board in office in fiscal 2018 be approved for their activities in fiscal 2018.

6. Resolution on the election of the auditors of the annual financial statements and the consolidated financial statements for fiscal 2019 as well as the auditors for the audit review of the interim financial statements and management report of the Group as of June 30, 2019

The Supervisory Board proposes the election of

KPMG AG Wirtschaftsprüfungsgesellschaft, Berlin,

as auditors of the annual financial statements and the consolidated financial statements for fiscal 2019 as well as for the audit review of the interim financial statements and management report of the Group as of June 30, 2019.

7. Supervisory Board elections

The Supervisory Board proposes the election of the following persons as representatives of the shareholders to the Supervisory Board with effect from the end of this Annual General Meeting:

- Dr. Wolfgang Büchele,
- Michael Kleinemeier,
- Renate Koehler,
- Helene von Roeder,
- Helga Rübsamen-Schaeff,
- Dr. Daniel Thelen.

The appointment shall be valid for the period ending with the conclusion of the Annual General Meeting resolving to approve the actions of the Supervisory Board for the fourth year following the beginning of the term of office. The fiscal year in which the term of office commences is not included in the calculation.

Notes to Agenda Item 7:

The Supervisory Board of the company consists of 16 members. Pursuant to Sections 278 (3), 96 (1), 101 (1) and (2) AktG, Section 7 (1) No. 2 of the German Co-Determination Act (hereinafter "MitbestG") and Article 15 (1) and Article 6 (5) of the Articles of Association of the company, the Supervisory Board is composed of eight members elected by the employees, six members elected by the Annual General Meeting as well as two members appointed by the holder of the registered share. On conclusion of the Annual General Meeting on April 26, 2019, the terms of office of the Supervisory Board members elected at the 2014 Annual General Meeting Dr. Wolfgang Büchele, Michaela Freifrau von Glenck, Albrecht Merck, Prof. Dr. Helga Rübsamen-

Schaeff, Prof. Dr. Gregor Schulz and Prof. Dr. Theo Siegert will expire. On conclusion of the Annual General Meeting on April 26, 2019, the terms of office of the appointed Supervisory Board members Dr. Siegfried Karjetta and Tobias Thelen will also end. The members appointed to the Supervisory Board with effect from the end of this General Meeting until the conclusion of the Annual General Meeting 2024 are Peter Emanuel Merck and Dr. Simon Thelen.

Taking into consideration the specific objectives the Supervisory Board has defined with respect to its composition, the profile of skills and expertise for the entire board elaborated by the Supervisory Board as well as the diversity policy and supported by the proposal by the Nomination Committee, the Supervisory Board proposes that the individuals named under Agenda Item 7 be elected to the Supervisory Board as representatives of the shareholders with effect from the end of the Annual General Meeting. The objectives and the profile of skills and expertise were confirmed by the Supervisory Board in their current version on February, 26 2019 and, including the status of implementation, are published in the Corporate Governance Report for the 2018 financial year. This report is contained in the 2018 annual report and is available on the company's website at www.merckkgaa-darmstadt-germany.com/agm.

In accordance with Section 5.4.1 (5) of the German Corporate Governance Code, the Supervisory Board has assured itself that the proposed candidates will be able to meet the expected time requirements.

In particular, Helene von Roeder has expertise in the fields of accounting or auditing of financial statements within the meaning of Section 100 (5) AktG.

Pursuant to Section 96 (2) sentence 1 AktG, the Supervisory Board must consist of at least 30 percent women and at least 30 percent men. In accordance with Section 96 (2) sentence 3 AktG, the shareholder representatives' side objected vis-à-vis the Chairman of the Supervisory Board to the overall fulfilment (*Gesamterfüllung*) on the basis of a resolution passed by a majority. The Supervisory Board must therefore be made up of at least two women and at least two men both on the side of the shareholders and on the side of the employees in order to meet the minimum requirement in accordance with Section 96 (2) sentence 1 AktG. Following the election of the candidates proposed by the Supervisory Board, the Supervisory Board would consist of three women and three men on the shareholders' side, so that the minimum requirement would continue to be fulfilled.

In the opinion of the Supervisory Board, the candidates proposed for election to the Supervisory Board are to be regarded as independent within the meaning of the definition of the German Corporate Governance Code. The corresponding declaration on the independence of the Supervisory Board candidates can be found on the company's website at www.merckkgaa-darmstadt-germany.com/agm.

In accordance with Section 5.4.3 sentence 3 of the German Corporate Governance Code, the Supervisory Board announces that Dr. Wolfgang Büchele shall be proposed for election as Chairman of the Supervisory Board in the event of his election to the Supervisory Board.

The Annual General Meeting is not required to follow the election proposals. It is planned to vote on the proposed candidates separately, with the elections being carried out individually. **Annex 1** of this Agenda particularly provides information on the profession, residence and memberships of the proposed persons in other statutory supervisory boards and comparable control bodies in Germany and abroad. **Annex 2** to this Agenda contains the curricula vitae of the proposed candidates. These are also available on the Company's website (www.merckkgaa-darmstadt-germany.com/agm).

Requirements for participating in the Annual General Meeting and exercising voting rights

1. Registration and evidence of share ownership

In accordance with Article 22 (1) and (2) of the Articles of Association of the company, to be eligible to participate in the Annual General Meeting and to exercise voting rights, shareholders must have registered with the company by no later than **April 19, 2019 (24:00 CEST)** under the following address and submitted evidence of share ownership related to the beginning of **April 5, 2019** (0:00 CEST, "record date") and issued by the custodial bank or financial institute to the following address:

**Merck KGaA
Darmstadt, Germany
c/o Deutsche Bank AG
Securities Production
General Meetings
Postbox 20 01 07
60605 Frankfurt am Main
Germany
or telefax: +49 69 12012-86045
or email: wp.hv@db-is.com**

Registration and evidence of share ownership must be in text form (Section 126b German Civil Code – hereinafter "BGB") in either German or English.

Following receipt of registration and evidence of share ownership, the admission ticket to the Annual General Meeting will be sent to the shareholder entitled to participate in the Annual General Meeting or his/her authorized representative. In order to ensure the timely receipt of the admission tickets, we kindly request shareholders to be sure to send their registration and evidence of share ownership to the company in a timely manner. In contrast to registration, however, the admission ticket not required for participation, instead serving merely to simply the process at admission control for entry to the General Meeting.

2. Meaning of the record date

The record date is the date that determines the extent and exercise of participation and voting rights at the Annual General Meeting. In relation to the company, individuals who wish to participate in the Annual General Meeting or to exercise voting rights must be deemed to be shareholders by having submitted evidence of share ownership by the record date. Eligibility to participate or the extent of voting rights is determined exclusively by share ownership on the record date. Changes in share ownership after the record date have no significance here. The record date does not involve a suspension of the ability to sell the shares held. Also in the event of the complete or partial sale of the shares owned after the record date, share ownership on the record date is exclusively definitive for participation and exercising voting rights. This means that the sale of shares after the record date has no impact on eligibility to participate or to exercise voting rights. This applies accordingly to the acquisition of additional shares after the record date. Persons who do not yet own shares as of the record date, and only become shareholders thereafter, are only entitled to participate or to vote for the shares they hold insofar as they are authorized by the previous shareholder to represent them or to exercise their rights on their behalf. The record date is of no relevance to a possible dividend entitlement.

3. Voting by proxy

Shareholders who do not wish to attend the Annual General Meeting personally may also have their voting rights exercised by an authorized representative, e.g. by a bank or shareholder association, or by a proxy appointed by the company who is bound to vote in accordance with the shareholder's instructions or by another third party. Pursuant to the aforementioned provisions, timely registration and evidence of share ownership are also required in the case of voting right proxies.

The authorization, its revocation and evidence thereof vis-à-vis the company must be given in text form or electronically via a web-based authorization system on the company's website (www.merckkgaa-darmstadt-germany.com/agm) if neither a credit institution, an institution or an undertaking or equal status within the meaning of Sections 135 (10) and 125 (5) AktG nor a shareholder association or person within the meaning of Section 135 (8) AktG is authorized to exercise the voting rights.

Shareholders wishing to authorize a proxy are kindly requested to use the form provided by the company. It is sent to persons who register correctly together with the admission ticket.

Shareholders can use the web-supported proxy authorization system for proxy authorization. In order to use the web-supported authorization system, it is necessary to enter the admission ticket number as well as a special code that can also be found on the admission ticket.

The web-supported authorization system simultaneously serves as an electronic means of transmitting evidence to the company of having appointed a proxy. For organizational reasons, the use of the web-supported authorization system on the day of the Annual General Meeting (April 26, 2019) can only be offered until the end of the speech by the Chairman of the Executive Board.

The authorization, its revocation and evidence of having authorized a proxy can also be transmitted to the company prior to the Annual General Meeting by surface mail, by fax or by email to the following address:

Merck KGaA
Darmstadt, Germany
c/o Computershare Operations Center
80249 Munich
Germany
or telefax: +49 89 30903-74675
or email: MRK-hv2019@computershare.de

Providing evidence to the company of having authorized a proxy can also proceed on the day of the Annual General Meeting if the proxy presents the evidence (e.g. the original or a copy of the authorization) at the registration desk.

When authorizing credit institutions or institutes or companies of equal status pursuant to Section 135 (10) in conjunction with Section 125 (5) AktG as well as shareholder's associations or persons of equal status pursuant to Section 135 (8) AktG to exercise voting rights, the authorization must be recorded by the proxy holder in a verifiable manner. The authorization must be completed in full and may only contain statements related to the exercise of voting rights. Shareholders wishing to authorize credit institutions or institutes or companies of equal status pursuant to Section 135 (10) in conjunction with Section 125 (5) AktG as well as shareholder's associations

or persons of equal status pursuant to Section 135 (8) AktG should come to an agreement with this party about the form of the authorization.

In addition, we continue to offer our shareholders the possibility to exercise their voting rights through a proxy appointed by our company. For this purpose, these proxies must be given the required authorization and instructions on how the votes are to be cast. The proxies are obliged to vote in line with the instructions given to them; without instructions from the shareholder, the proxies appointed by the company are not authorized to exercise the shareholder's voting rights. In case of absence of express and clear instructions, the proxy representative specified by the company shall abstain from voting on the relevant voting item. They will not accept any instructions relating to requests to speak, asking questions or bringing forward motions or nominations, or the filing of objections against resolutions by the General Meeting.

Prior to the Annual General Meeting, authorizations and instructions to the proxies appointed by the company can be granted electronically via the Web-based authorization system or via the form entitled "Authorizations and instructions for proxy voting by representatives appointed by the company", which can be found on the admission ticket which is sent to shareholders after registration. Authorizations and instructions to the proxies appointed by the company that are submitted to the company by surface post, by fax or by email must be received by the company no later than April 25, 2019 (15:00 CEST) at the following address:

Merck KGaA
Darmstadt, Germany
c/o Computershare Operations Center
80249 Munich
Germany
or telefax: +49 89 30903-74675
or email: MRK-hv2019@computershare.de

The same applies if shareholders wish to revoke the authorization granted to the proxy appointed by the company via the aforementioned procedure. Authorizations and instructions may also be granted, amended or revoked via the web-based authorization system even during the Annual General Meeting (April 26, 2019) until the Chairman of the Executive Board has completed his speech.

Also in the event of the shareholder being represented by a third party or by the proxy appointed by the company, it is necessary to register and to submit evidence of share ownership before the specified deadlines as described in the foregoing.

If the shareholder authorizes more than one person, the company may reject one or more of them.

Shareholders will receive further details on participating in the Annual General Meeting as well as on granting authorization and issuing voting instructions together with the admission ticket or by visiting the website of the company (www.merckkgaa-darmstadt-germany.com/agm).

**Disclosure of rights of shareholders in accordance
with Section 278 (3) in conjunction with
Sections 122 (2), 126 (1), 127, 131 (1) AktG**

1. Motions to add agenda items pursuant to Sections 278 (3) and 122 (2) AktG

Pursuant to Sections 278 (3) and 122 (2) AktG, shareholders whose shares amount in aggregate to not less than a twentieth of the share capital or represent an amount of the share capital corresponding to € 500,000.00, may demand that items are put on the agenda and published. Each new item shall be accompanied by an explanation or a draft proposal. Such requests are to be made in writing and must be received by the company at least 30 days before the General Meeting, i.e., at the latest by the end of March 26, 2019 (24:00 CEST) at the following address:

**Merck KGaA
Darmstadt, Germany
- HV-Büro -
Frankfurter Strasse 250
64293 Darmstadt
Germany**

Those submitting such requests must document that they have been the owners of the shares for the duration of at least 90 days prior to the day of the receipt of the request and hold the shares until such time as a decision

of the Executive Board is rendered regarding their request (Section 278 (3), Section 122 (2), Section 122 (1) sentence 3 AktG and Section 70 AktG).

The announcement and provision of requests for supplements is carried out in the same way as convening notices.

2. Motions and nominations by shareholders pursuant to Sections 278 (3), 126 (1) and 127 AktG

Shareholders of the company may submit countermotions against proposals of the Executive Board and the Supervisory Board with respect to specific Agenda Items as well as nominations for the election of the auditor and/or supervisory board members. If countermotions are meant to be made accessible, they must include an explanatory statement; nominations do not require an explanatory statement.

Any countermotions and nominations received by the company at the following address no later than 14 days before the day of the General Meeting, i.e. by April 11, 2019, 24:00 (CEST), will be published immediately after receipt on the internet at (www.merckkgaa-darmstadt-germany.com/agm) including the name of the shareholder and – in case of motions – including the explanatory statement under the further conditions of Sections 278 (3), 126 and 127 AktG. Possible statements by the administration will also be published at the same internet address.

Countermotions to the Agenda and nominations are to be directed exclusively to the following address of the company:

Merck KGaA
Darmstadt, Germany
- HV-Büro -
Frankfurter Strasse 250
64293 Darmstadt
Germany
or telefax: +49 6151 72-9877
or email: hauptversammlung@merckkgaa-darmstadt-germany.com

Any countermotions sent to any other addresses cannot be considered.

3. Shareholders' right to information in accordance with Section 131 (1) AktG

Upon request, every shareholder will be provided with information by the Executive Board at the Annual General Meeting regarding the company's affairs, to the extent that such information is necessary to permit a proper evaluation of an agenda item. The duty to provide information also extends to the company's legal and business relations with any affiliate as well as to the situation of the Group and the entities included in the consolidated financial statements.

4. Further details on the rights of shareholders

Further details on the rights of shareholders pursuant to Section 278 (3) AktG in conjunction with Sections 122 (2), 126 (2), 126 (1), 127, and 131 (1) AktG can be found on the website of the company (www.merckkgaa-darmstadt-germany.com/agm).

**Information and Documents for the
Annual General Meeting; company website**

The information pursuant to Section 124a AktG and further information relating to the Annual General Meeting is available on the following website of the company once the Annual General Meeting has been convened:

www.merckkgaa-darmstadt-germany.com/agm

In particular, the documents mentioned with reference to agenda items 1 and 7 are available there.

These documents can also be inspected at the business offices of

**Merck KGaA
Darmstadt, Germany
Visitor Reception
Frankfurter Strasse 131
64293 Darmstadt
Germany**

Upon request, each shareholder will receive a copy of the abovementioned documents without undue delay and free of charge. The request is to be sent

to the address referred to above in Section 2 (Motions by shareholders pursuant to Section 126 (1) AktG).]

The documents that are required to be made available will also be accessible for inspection during the Annual General Meeting.

Any requests from shareholders for items to be included on the agenda, countermotions and nominations of candidates for election that require publication will also be made available on the aforementioned website.

Total number of shares and voting rights when the General Meeting is convened

As of the date on which the General Meeting is convened, the subscribed capital of the company amounts to € 168,014,927.60 (in words: one hundred and sixty-eight million, fourteen thousand nine hundred twenty-seven euros and sixty cents), divided into 129,242,251 no par value bearer shares plus one registered share. Each of the total number of 129,242,252 shares grants the holder one vote, which means that as of the date on which the General Meeting is convened, 129,242,252 voting rights exist.

Broadcasting of the Annual General Meeting on the Web

As authorized by the Chairman of the Meeting, all shareholders as well as interested members of the public can follow the Annual General Meeting live on the website of the company (www.merckkgaa-darmstadt-germany.com/agm) on April 26, 2019 from 10:00 a.m. CEST until the Chairman of the Executive Board completes his speech. The speech by the Chairman of the Executive Board as well as the voting results will likewise be published on the aforementioned website after the Annual General Meeting.

5. Notes on data protection

The legally compliant collection and processing of shareholders' personal data is of great importance to the company. The collection and processing of personal data (name, address, email address, number of shares, class of shares, type of share ownership and number of admission ticket) is carried out in accordance with the applicable data protection laws.

The collection and processing of personal data is absolutely necessary for the participation in the Annual General Meeting and is carried out in order to facilitate the participation of each registered shareholder. The company is responsible for collection and processing. It is our legal obligation to hold an Annual General Meeting and to enable the exercise of voting rights. For this purpose we have to process the named data. The legal basis for the processing of your personal data is the German Stock Corporation Act in conjunction with Article 6 (1) lit. c) DSGVO.

Computershare Deutschland GmbH & Co. KG, Munich, Germany, as external service provider commissioned for the purpose of holding the Annual General Meeting, shall only receive such personal data as is necessary for the performance of the commissioned service and shall process the data exclusively on behalf of and in accordance with instructions from the company.

Your data will only be processed in countries belonging to the European Union.

All shareholders have the right to access, correction, restriction, objection and deletion at any time with regard to the processing of their personal data, as well as the right to data transmission in accordance with Chapter III of the DSGVO.

Shareholders may assert these rights vis-à-vis the company free of charge using the following contact details:

Merck KGaA
Darmstadt, Germany
- HV-Büro -
Frankfurter Strasse 250
64293 Darmstadt
Germany
or telefax: +49 6151 72-9877
or email: hauptversammlung@merckkgaa-darmstadt-germany.com

The company's data protection officer can be reached at:

Merck KGaA
Darmstadt, Germany
- Data Protection Officer -
Frankfurter Strasse 250
64293 Darmstadt
Germany
or telefax: +49 6151 72-915167
or email: datenschutz@merckkgaa-darmstadt-germany.com

Further information on data protection, in particular on our storage obligations and your rights, is available on the company's website (www.merckkgaa-darmstadt-germany.com/agm).

Merck Kommanditgesellschaft auf Aktien, Darmstadt, Germany, March 2019

The Executive Board

Annex 1

Information on the Supervisory Board candidates proposed for election under Item 7 of the Agenda

- on profession, residence and memberships of

(a) other statutory supervisory boards and

(b) comparable German and foreign supervisory bodies of economic enterprises

Dr. Wolfgang Büchele

Römerberg, Germany, Chairman of the Executive Board of Exyte AG, Stuttgart, Germany

(a) Gelita AG (not publically listed), Eberbach, Germany (Deputy Chairman of the Supervisory Board)

(b) E. Merck KG, Darmstadt, Germany and Kemira Oyi, Helsinki, Finland

Michael Kleinemeier

Heidelberg, Germany, Member of the Executive Board of SAP SE, Walldorf, Germany

(a) innogy SE, Essen, Germany

(b) E. Merck KG, Darmstadt, Germany

Renate Koehler

Darmstadt, Germany, Head of Engel-Apotheke, Darmstadt, Germany

No further mandates

Helene von Roeder

Frankfurt am Main, Germany, Member of the Executive Board (CFO) of Vonovia SE, Bochum, Germany

(b) E. Merck KG, Darmstadt, Germany; AVW Versicherungsmakler GmbH, Hamburg, Germany and Vonovia Finance B.V., Amsterdam, Netherlands

Prof. Dr. Helga Rübsamen-Schaeff

Langenburg, Germany, Chairperson of the Advisory Board of AiCuris Antiinfective Cures GmbH, Wuppertal, Germany

(a) 4SC AG, Planegg-Martinsried, Germany

(b) E. Merck KG, Darmstadt, Germany and University Medical Center Bonn, Germany

Dr. Daniel Thelen

Cologne, Germany, Head of Infrastructure Development Region West, DB Netz AG, Frankfurt am Main/Duisburg, Germany

(b) E. Merck KG, Darmstadt, Germany

With reference to Section 5.4.1 (6) of the German Corporate Governance Code, it is declared that the proposed candidates, with the exception of Ms. Renate Koehler, are each members of the Board of Partners of E. Merck KG. Renate Koehler and Dr. Daniel Thelen are limited partners of E. Merck KG. Furthermore, in the view of the Supervisory Board of Merck KGaA, Darmstadt, Germany none of the proposed candidates has any personal or business relationship with Merck KGaA, Darmstadt, Germany or its subsidiaries, Merck KGaA, Darmstadt, Germany's executive bodies or a substantial shareholder of Merck KGaA, Darmstadt, Germany that are to be disclosed in accordance with this provision.

Annex 2

Curricula vitae of the candidates proposed for election to the Supervisory Board under Item 7 of the Agenda:

Dr. Wolfgang Büchele

Qualification:	Chemist
Current occupation:	Chief Executive Officer Exyte AG, Stuttgart, Germany
Geburtsdatum:	August 11, 1959
Nationality:	German
Gender:	Male
Education:	
1979-1984	University degree course in chemistry, University of Ulm (concentration in solid state chemistry), Degree: Graduate Chemist
1984-1987	Assistant in inorganic chemistry, University of Ulm under Professor Dr. rer. nat. Lentz
1987	Doctorate (<i>Dr. rer. nat</i>) with a specialization in inorganic chemistry
Professional career:	
BASF AG	
1987-1990	Research chemist for industrial catalysts
1990-1993	Research group head (industrial catalysts)
1993-1997	Head of Regional Marketing Catalysts Asia, Hong Kong
1997-1999	Head of Global Marketing Cosmetic Raw Materials
1999-2001	Head of Business Management Fine Chemicals Europe

2001-2003	President of Eastern Europe, Africa, West Asia Regional Division
2003-2005	President, Performance Chemicals Supervisory Board Chairman BASF Drucksysteme GmbH, Stuttgart, Germany
2003-2007	Member of the Site Management Committee of the Ludwigshafen site
2005-2007	President, Fine Chemicals
2007	Appointed to the Management Board effective January 1, 2008 with responsibility for oil and gas, the region Europe as well as Global Procurement & Logistics

The Blackstone Group LLP

2008	Project Advisor (incl. minority interest in Evonik AG)
------	--

Permira Beteiligungsberatung GmbH, Frankfurt, Germany

2008-2011	Senior Advisor
-----------	----------------

BorsodChem Zrt. , Kazincbarcika/Ungarn

2008-2011	Chief Executive Officer
2009-2011	Chief Executive Officer and Chairman of the Board
2011	Chief Executive Officer and Member of the Board

Kemira Oyj., Helsinki/Finnland

2009-2011	Member of the Board
2012	Advisor of the Chairman and Member of the Board
2012-2014	Chief Executive Officer
Since 2014	Member of the Board of Directors

Linde AG, München

2014-2016	Chairman of the Board
-----------	-----------------------

M+W Group GmbH, Stuttgart

2017-2018 Chief Executive Officer and Spokesman of the Management Board

Exyte AG, Stuttgart

Since September 2018 Chief Executive Officer

Member of the Supervisory Board of Merck KGaA, Darmstadt, Germany since:

July 1, 2009

Further board positions:

E. Merck KG, Darmstadt, Germany (Member of the Board of Partners)

Kemira Oyi, Helsinki, Finland (Member of the Board of Directors)

Gelita AG (not publically listed), Eberbach, Germany (Vice Chairman of the Supervisory Board)

Other:

Member of Baden-Badener Unternehmergespräche

Member of Rotary International

Chairman of German Eastern Business Association

Member of the University Council of the Technische Universität München

Michael Kleinemeier

Qualification:	Diplom Kaufmann
Current occupation:	Member of the Executive Board of SAP SE, Walldorf, Germany, SAP Digital Business Services
Date of birth:	March 13, 1957
Nationality:	German
Gender:	Male
Education:	
1981-1986	University of Paderborn, Diplom-Kaufmann
Professional career:	
1986-1988	System engineer at Krupp Atlas Datensysteme, Essen, Germany
1989-1999	Several executive level positions within SAP AG including Sales, Consulting and Training
1999-2001	Member of the Executive Board of Itelligence AG
2001-2002	Sales Director of the German subsidiary of SAP AG
2002-2003	Managing Director of the German branch office of SAP AG
2003-2007	Regional President of the EMEA Central Region, SAP AG
2007-2008	Member of the Executive Council and Corporate Officer of SAP AG / Head of Industries
03-08 2008	Co-CEO of Häussler Management Holding Stuttgart, Germany
2009	Founder of e-mobiligence GmbH
2010-2012	Regional President of the DACH Region, SAP AG
2012	President of Global End-to-End Services in parallel to his role as Regional President of the DACH Region and as Corporate Officer, SAP AG

2013-2014	Regional President of the Middle & Eastern Europe Region, SAP SE; Corporate Officer of SAP AG
Since 2015	Member of the Executive Board of SAP SE, SAP Digital Business Services

Further board positions:

E. Merck KG, Darmstadt, Germany (Member of the Board of Partners)

innogy SE, Essen, Germany (Member of the Supervisory Board)

Other:

German Eastern Business Association, BDI, BITKOM e.V.

Renate Koehler

Qualification:	Pharmacist
Current occupation:	Pharmacist and Head of Engel-Apotheke, Darmstadt, Germany
Date of birth:	July 6, 1955
Nationality:	German
Gender:	Female
Education:	
1974-1977	Studies for the higher teaching profession with intermediate examination in biology, chemistry, sports in Gießen, Germany
1977-1981	Pharmacy studies in Freiburg, Germany
1981	Approbation as pharmacist
Professional career:	
1981-1982	Employed pharmacist in Karlsruhe, Germany
1983	Employed pharmacist at Engel-Apotheke, Darmsatdt, Germany
1991	Business takeover of Engel-Apotheke, Darmstadt, Germany
Further board positions:	No further mandates
Other:	
Since 2012	Board of Directors Krebshilfe Südhessen e.V.
Since 2015	Member of the Board of Trustees of Bürgerstiftung Darmstadt

Helene von Roeder

Qualification:	Physicist
Current occupation:	Member of the Board (CFO) of Vonovia SE, Bochum, Germany
Date of birth:	June 5, 1970
Nationality:	German
Gender:	Female
Education:	
1989-1993	Study of theoretical physics, Ludwig-Maximilian-Universität München
1993-1994	Study of theoretical astrophysics, University of Cambridge
Professional career:	
1995-2000	Deutsche Bank AG, London, UK
2000-2004	UBS AG, Frankfurt am Main, Germany and London, UK
2004-2014	Morgan Stanley Bank AG, Frankfurt am Main – most recently member of the Executive Board of Morgan Stanley Bank AG and Head of Global Capital Markets for Germany and Austria
2014-2018	Credit Suisse – CEO Germany, responsible for the business of Credit Suisse in Germany, Austria and CEE
Since 2018	Vonovia SE – Member of the Executive Board (CFO), responsible for Controlling, Finance, Accounting, Tax, Valuation, Procurement, Insurance and Third Party Management
Further board positions:	
	E. Merck KG, Darmstadt, Germany (Member of the Board of Partners)

AVW Versicherungsmakler GmbH, Hamburg, Germany (Member of the Supervisory Board and Member's Council)

Vonovia Finance B.V., Amsterdam, Netherlands (Member of the Supervisory Board)

Other: Honorary member of the Development Board of the European Molecular Biology Laboratory

Prof. Dr. Helga Rübsamen-Schaeff

Qualification:	Chemist
Current occupation:	Chairperson of the Advisory Board of AiCuris Antiinfective Cures GmbH, Wuppertal, Germany
Date of birth:	January 13, 1949
Nationality:	German
Gender:	Female
Education:	
1967-1971	Studies of Chemistry, University of Münster, degree: Diploma
1973	Dr. rer. Nat. degree, University of Münster
Professional career:	
1973-1979	Post-Doc, University of Münster, Germany Cornell University, Ithaca, NY, USA, Gießen, Germany
1979-1982	Habilitation scholar (<i>Deutsche Forschungsgemeinschaft</i>), University of Cologne, Germany, and Paul-Ehrlich Institut Frankfurt am Main, Germany
1982-1986	Head of division, Institute for Biomedical Research Georg-Speyer-Haus, Frankfurt am Main, Germany

1983	Habilitation University of Frankfurt am Main, Germany
1983 and 1985	Guest scientist, Harvard University, Cambridge, MA, USA
1987-1993	Scientific and Managing Director, Institute for Biomedical Research Georg-Speyer-Haus, Frankfurt am Main, Germany
Since 1988	Professor (Biochemistry and Virology), University of Frankfurt am Main, Germany
1994-2001	Vice President, head of institute of virology, Bayer AG, Leverkusen, Germany
2001-2006	Senior Vice President, head of anti-infective research, Bayer AG, Leverkusen, Germany
2006-2015	Managing Director (CEO), AiCuris GmbH & Co. KG, Wuppertal, Germany
Since 03/2015	Chairperson of the Advisory Board of AiCuris Antiinfective Cures GmbH, Wuppertal, Germany

Member of the Supervisory Board of Merck KGaA, Darmstadt, Germany since:

May 9, 2014

Further board positions:

E. Merck KG, Darmstadt, Germany (Member of the Board of Partners)

4SC AG, Planegg-Martinsried, Germany (Member of the Supervisory Board)

University Medical Center Bonn, Germany (Member of the Supervisory Board)

Other:

Member of Leopoldina, Nationale Akademie der Wissenschaften,

Awardee of Deutscher Zukunftspreis, German President's Award for Innovation in Science and Technology 2018

Dr. Daniel Thelen

Qualification: Fully qualified German lawyer, Master of Business Administration

Current occupation: Head of Infrastructure Development Department West Region, DB Netz AG, Frankfurt am Main/Duisburg, Germany

Date of birth: October 2, 1974

Nationality: German

Gender: Male

Education:

1995-2000 Law studies, University of Cologne and Université de Lausanne, Switzerland

2001-2004 Legal clerkship, Cologne Higher Regional Court, inter alia Metro AG.

2008-2010 Studies at Bradford University School of Management, Bradford (UK) / Bonn, Degree: Master of Business Administration

Professional career:

2005-2006 Lawyer in the fields of commercial/corporate law, Seitz Partnerschaftsgesellschaft mbB, Cologne, Germany

2006-2008 Consultant, Lawyer in the fields of insolvency-restructuring, TMS Restart GmbH, Cologne, Germany

2008-2010 Senior Consultant, Lawyer in the fields of restructuring, Buchalik Brömmekamp Unternehmensberatung GmbH, Düsseldorf, Germany

2011-2013 Customer manager for international rail freight transport, DB Netz AG, Headquarters, Frankfurt am Main, Germany

2016 Operative Project Manager, DB Netz AG,
Headquarters, Frankfurt am Main, Germany

Since 2013 Head of Infrastructure Development Department
West Region, DB Netz AG, Frankfurt am
Main/Duisburg, Germany

Further board positions:

E. Merck KG, Darmstadt, Germany (Member of the
Board of Partners)

Member of the advisory board of two companies
for the operation of photovoltaic systems